# Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1

> **NCT05832931** · PHASE3 · COMPLETED · sponsor: **Pathalys Pharma** · enrollment: 362 (actual)

## Conditions studied

- Secondary Hyperparathyroidism
- End-stage Kidney Disease (ESKD)

## Interventions

- **DRUG:** PLS240
- **DRUG:** Placebo
- **DRUG:** Open-Label Extension PLS240

## Key facts

- **NCT ID:** NCT05832931
- **Lead sponsor:** Pathalys Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-28
- **Primary completion:** 2025-07-28
- **Final completion:** 2025-07-28
- **Target enrollment:** 362 (ACTUAL)
- **Last updated:** 2025-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05832931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05832931, "Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05832931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*